{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-014613","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.055557+00:00","generated_at":"2026-06-04T09:44:20.180947+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive Therapeutics prices $75M public offering of 16.7M shares at $4.50 per share","bullets":["Offering of 16,666,667 shares at $4.50 per share; gross proceeds ~$75M, net ~$69.8M.","Underwriters granted 30-day option to purchase up to 2,500,000 additional shares.","Proceeds to advance Anaphylm (epinephrine) sublingual film and Libervant (diazepam) buccal film.","Closing expected on or about March 22, 2024; Leerink Partners and Piper Sandler lead.","Company expects net proceeds plus existing cash to fund operations through December 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-014613","json":"https://secwatch.observer/filing/0001140361-24-014613.json","markdown":"https://secwatch.observer/filing/0001140361-24-014613.md","text":"https://secwatch.observer/filing/0001140361-24-014613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/0001140361-24-014613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/ny20024600x3_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:44:20.180947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebc236acc646451f34f3a3222ef2bce8e93eba34","claim":"Aquestive Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Piper Sandler & Co. valued at $69.8 million net proceeds (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, Aquestive Therapeutics, Inc. (the \"Company\") entered into an underwriting agreement (the \"Underwriting Agreement\") by and among the Company and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the \"Underwriters\"), relating to an underwritten public offering of 16,666,667 shares of the Company's common stock, par value $0.001 per share (\"Common Stock\"), at a public offering price of $4.50 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/0001140361-24-014613-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC and Piper Sandler & Co."},{"label":"Value","value":"$69.8 million net proceeds"},{"label":"Effective","value":"2024-03-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}